Laurus Labs receives licence from DRDO to manufacture and market COVID drug 2DG

Laurus Labs has already applied with the Central Drugs Standard Control Organisation for emergency use authorization for 2DG, the company said.

Published: 02nd July 2021 02:44 PM  |   Last Updated: 02nd July 2021 02:44 PM   |  A+A A-

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan release first batch of Anti-COVID drug 2DG developed by DRDO

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan releasing the first batch of Anti-COVID drug 2DG developed by DRDO on 17 May, 2021. (File photo | ANI)

By PTI

NEW DELHI: Drug firm Laurus Labs on Friday said it has received the licence from Defence Research and Development Organisation to manufacture and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

"Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG," it added.

On June 28, pharma major Dr Reddy's announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet.

Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous day's close.

Now we are on Telegram too. Follow us for updates
India Matters

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

Videos
Gallery